These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 22410384)

  • 1. The risk of infections in HIV-HCV coinfected patients during antiviral therapy with pegIFN+RBV.
    Payer BA; Reiberger T; Breitenecker F; Aichelburg MC; Schuster C; Heil PM; Scherzer TM; Ferenci P; Rieger A; Peck-Radosavljevic M;
    J Infect; 2012 Aug; 65(2):142-9. PubMed ID: 22410384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections.
    Serrano-Villar S; Quereda C; Moreno A; Pérez-Elías MJ; Casado JL; Royuela A; Dronda F; Navas E; Hermida JM; Moreno S
    Clin Infect Dis; 2013 Aug; 57(3):458-64. PubMed ID: 23575196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower Ribavirin Plasma Concentrations in HCV/HIV-Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage.
    Deenen MJ; de Kanter CT; Dofferhoff AS; Grintjes-Huisman KJ; van der Ven AJ; Fleuren HW; Gisolf EH; Koopmans PP; Drenth JP; Burger DM
    Ther Drug Monit; 2015 Dec; 37(6):751-5. PubMed ID: 26102531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient.
    Payer BA; Reiberger T; Rutter K; Beinhardt S; Staettermayer AF; Peck-Radosavljevic M; Ferenci P
    J Clin Virol; 2010 Oct; 49(2):131-3. PubMed ID: 20709593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interferon-alpha and ribavirin combination therapy for co-infection of hepatitis C virus and human immunodeficiency virus].
    Zheng YH; He Y; Yang X; Gong GZ; Zhou HY; Zhang CY; Zhou W; Huang L; Ding PP; Li H
    Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):741-4. PubMed ID: 16248945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
    Reiberger T; Obermeier M; Payer BA; Baumgarten A; Weitner L; Moll A; Christensen S; Köppe S; Kundi M; Rieger A; Peck-Radosavljevic M
    Antivir Ther; 2011; 16(6):815-24. PubMed ID: 21900713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronic hepatitis C in patients with HIV/HCV coinfection with high CD4+ lymphocytes count].
    Inglot M; Szymczak A; Gładysz A; Małyszczak K; Zalewska M
    Przegl Epidemiol; 2007; 61(3):535-43. PubMed ID: 18069391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryoglobulinaemia vasculitis in patients coinfected with HIV and hepatitis C virus.
    Saadoun D; Aaron L; Resche-Rigon M; Pialoux G; Piette JC; Cacoub P;
    AIDS; 2006 Apr; 20(6):871-7. PubMed ID: 16549971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response.
    Bani-Sadr F; Krastinova E; Fromentin D; Piroth L; Rosenthal E; Quertainmont Y; Perronne C; Cacoub P; Pol S; Carrat F;
    J Viral Hepat; 2012 Jun; 19(6):431-5. PubMed ID: 22571905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
    Bani-Sadr F; Lapidus N; Bedossa P; De Boever CM; Perronne C; Halfon P; Pol S; Carrat F; Cacoub P; ;
    Clin Infect Dis; 2008 Mar; 46(5):768-74. PubMed ID: 18248298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy.
    Zaegel-Faucher O; Bregigeon S; Cano CE; Obry-Roguet V; Nicolino-Brunet C; Tamalet C; Dignat-George F; Poizot-Martin I
    AIDS; 2015 Jul; 29(12):1505-10. PubMed ID: 26244390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients.
    Guzmán-Fulgencio M; Jiménez JL; Berenguer J; Fernández-Rodríguez A; López JC; Cosín J; Miralles P; Micheloud D; Muñoz-Fernández MÁ; Resino S
    J Antimicrob Chemother; 2012 May; 67(5):1238-45. PubMed ID: 22294644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus.
    Hull MW; Rollet K; Odueyungbo A; Saeed S; Potter M; Cox J; Cooper C; Gill J; Klein MB;
    Clin Infect Dis; 2012 Jun; 54(12):1798-805. PubMed ID: 22460964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naive HIV/HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfected patients treated with antiretroviral therapy.
    Sitia G; De Bona A; Bagaglio S; Galli L; Paties CT; Uberti-Foppa C; Guidotti LG; Lazzarin A; Morsica G
    Antivir Ther; 2006; 11(3):385-9. PubMed ID: 16759056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus.
    Valle Tovo C; Alves de Mattos A; Ribeiro de Souza A; Ferrari de Oliveira Rigo J; Lerias de Almeida PR; Galperim B; Riegel Santos B
    Liver Int; 2007 Feb; 27(1):40-6. PubMed ID: 17241379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.
    Hatu G; Bailly F; Pourcelot E; Pradat P; Miailhes P; Maynard M; Parant F; Chiarello P; Livrozet JM; Zoulim F; Gagnieu MC
    BMC Infect Dis; 2014 Mar; 14():150. PubMed ID: 24650094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.
    Soriano V; Puoti M; Sulkowski M; Cargnel A; Benhamou Y; Peters M; Mauss S; Bräu N; Hatzakis A; Pol S; Rockstroh J
    AIDS; 2007 May; 21(9):1073-89. PubMed ID: 17502718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.